Pharma BD Deal Intelligence
Merck to acquire Imago for $1.35 billion, bolstering pipeline for drugs targeting bone marrow diseases with LSD1 inhibitor bomedemstat.
Merck announced the successful completion of the cash tender offer for all of the outstanding shares of common stock of Imago BioSciences at a purchase price…
Merck today announced it has entered into a definitive agreement to acquire Imago BioSciences, Inc. for $36.00 per share in cash for an approximate total…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Merck acquired Imago BioSciences for approximately $1.35 billion ($36.00 per share) in an all-cash tender offer, gaining bomedemstat, an oral LSD1 inhibitor in clinical development for myeloproliferative neoplasms including myelofibrosis.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Imago BioSciences Inc. (this deal) | 2022 | $1.4B | 60 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2022 deals · Merck & Co. Inc. deals · Hematology deals